Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-2 of 2
Keywords: BCG therapy
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Intravesical Bacillus Calmette-Guérin Prophylactic Treatment for Superficial Bladder Tumors: Results of a Controlled Prospective Study
Available to PurchaseSubject Area:
Further Areas
Journal:
Urologia Internationalis
Urol Int (1990) 45 (3): 137–141.
Published Online: 02 February 2010
..., instructions or products referred to in the content or advertisements. Bladder cancer Superficial bladder tumors BCG therapy Urol Int 1990;45:137-141 © 1990 S. Karger AG, Basel 0042-1138/90/0453-0137S2.75/0 Intravesical Bacillus Calmette-Guerin Prophylactic Treatment for Superficial Bladder Tumors...
Journal Articles
Urinary Fibronectin Levels in Patients Treated with Intravesical Bacillus Calmette-Guérin for Superficial Bladder Cancer
Available to PurchaseSubject Area:
Further Areas
Journal:
Urologia Internationalis
Urol Int (2000) 64 (4): 198–201.
Published Online: 17 January 2006
.... Fibronectin (FN), an important component of the extracellular matrix, has been found to play a role in BCG therapy. Some studies have shown that the soluble form of FN can compete efficiently with the matrix form of binding to the specific receptors on the bacteria and could consequently diminish the effect...
